Principle
A discovery call that does not change what the rep believes about the deal was not discovery. It was a product pitch wearing a different name and following a different agenda template. Most sales organisations cannot tell the difference, because both activities look completely identical from inside the CRM: a logged call, a set of notes, a stage that advances on schedule.
Behaviour
Genuine discovery produces new information the rep did not previously have: a budget constraint nobody had disclosed, a competing internal priority that could delay or kill the deal, a second decision-maker nobody had mapped or accounted for. That new information should visibly change something about the deal afterward, whether in strategy, in CRM stage, or at minimum in the rep's own private confidence level about the outcome. Most discovery calls, in practice, produce none of this. The rep works through a scripted, largely predetermined set of questions, receives answers that broadly confirm what they already assumed walking in, and moves the deal to the next stage regardless of what, if anything, was genuinely learned during the conversation.
The distinguishing signature here is not call length, question count, or even how thorough the notes appear afterward. It is whether anything about the deal materially changed as a direct, traceable result of the call. In a healthy, well-run pipeline, discovery calls regularly and routinely produce disqualification, redirection to a different buying committee member, or a materially different account strategy than the one the rep started with. In a pipeline running what we call Discovery Theatre, they almost never do, quarter after quarter, regardless of how many deals pass through the process.
A pipeline where discovery never changes anything is not qualifying deals. It is processing them.
Evidence
Pull a representative sample of discovery call notes across ten to fifteen open opportunities and check for one specific thing: did the deal's stage, its underlying strategy, or the rep's own stated confidence level change in the week immediately following the call. If the answer is consistently no across the sample, the organisation is running a scripted qualification ritual rather than genuine discovery, regardless of how professional or thorough the call notes look on the surface.
A second, faster diagnostic: listen to or read the transcript of three discovery calls and count how many questions asked were genuinely open and exploratory, with the rep authentically uncertain of the answer in advance, versus how many were closed questions specifically designed to elicit a particular, expected response that confirms an assumption. A ratio heavily weighted toward closed, leading questions is a strong indicator that the rep already believes they know the answer and is using the call to seek confirmation rather than new information.
Psychology
Real discovery is professionally uncomfortable in a specific way. It risks surfacing a genuine reason the deal won't work, and it risks surfacing that reason early, before the rep has invested weeks of effort, relationship-building, and internal forecast credibility into the opportunity. Scripted discovery is comfortable by comparison. It follows a known, well-rehearsed structure, produces broadly predictable answers, and allows the rep to move the deal forward confidently without ever having to confront anything that might genuinely complicate it.
Reps operating under sustained pipeline pressure, and reps who have internalised over time that pipeline volume is rewarded more consistently than pipeline quality, will gravitate toward the comfortable version of discovery every single time. Nobody in the organisation is explicitly instructing them to skip real discovery. The prevailing incentive structure simply makes the scripted version the path of least resistance, and human behaviour reliably follows the path of least resistance under pressure.
Commercial Risk
Discovery Theatre produces a specific and genuinely expensive failure mode for any commercial organisation running at scale: deals that continue to advance through the pipeline on the strength of assumptions that were never actually, rigorously tested, and that consequently fail later in the process, at a stage where the cost of that failure is considerably higher than it would have been earlier. A deal that should reasonably have been disqualified in week two instead consumes rep time, forecast credibility, and overall sales cycle length for two or three additional months before the untested assumption finally, inevitably surfaces and the deal collapses.
At the portfolio level, this pattern shows up as an average sales cycle that runs longer than the product and market would otherwise suggest, combined with a late-stage loss rate that is meaningfully higher than what the pipeline's early-stage qualification data would predict if that data were actually reliable.
Investment Committee Note